High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
05
03
2024
accepted:
10
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Vaccines have played a central role in combating the COVID-19 pandemic, but newly emerging SARS-CoV-2 variants are increasingly evading first-generation vaccine protection. To address this challenge, we designed "single-cycle infection SARS-CoV-2 viruses" (SCVs) that lack essential viral genes, possess distinctive immune-modulatory features, and exhibit an excellent safety profile in the Syrian hamster model. Animals intranasally vaccinated with an Envelope-gene-deleted vaccine candidate were fully protected against an autologous challenge with the SARS-CoV-2 virus through systemic and mucosal humoral immune responses. Additionally, the deletion of immune-downregulating viral genes in the vaccine construct prevented challenge virus transmission to contact animals. Moreover, vaccinated animals displayed neither tissue inflammation nor lung damage. Consequently, SCVs hold promising potential to induce potent protection against COVID-19, surpassing the immunity conferred by natural infection, as demonstrated in human immune cells.
Identifiants
pubmed: 39472701
doi: 10.1038/s41541-024-00992-z
pii: 10.1038/s41541-024-00992-z
doi:
Types de publication
Journal Article
Langues
eng
Pagination
206Informations de copyright
© 2024. The Author(s).
Références
Beesley, L. J. et al. SARS-CoV-2 variant transition dynamics are associated with vaccination rates, number of co-circulating variants, and convalescent immunity. eBioMedicine 91, 104534 (2023).
pubmed: 37004335
pmcid: 10065418
doi: 10.1016/j.ebiom.2023.104534
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
pubmed: 33378609
doi: 10.1056/NEJMoa2035389
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
pubmed: 33301246
doi: 10.1056/NEJMoa2034577
Sadoff, J. et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N. Engl. J. Med. 386, 847–860 (2022).
pubmed: 35139271
doi: 10.1056/NEJMoa2117608
Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021).
pubmed: 33306989
pmcid: 7723445
doi: 10.1016/S0140-6736(20)32661-1
Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med. 28, 1063–1071 (2022).
pubmed: 35189624
pmcid: 9117141
doi: 10.1038/s41591-022-01753-y
Muik, A. et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera. Science 375, 678–680 (2022).
pubmed: 35040667
pmcid: 9836206
doi: 10.1126/science.abn7591
Wang, Y. et al. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc. Natl Acad. Sci. USA 118, e2102775118, https://doi.org/10.1073/pnas.2102775118 (2021).
doi: 10.1073/pnas.2102775118
pubmed: 34193524
pmcid: 8307828
Nouailles, G. et al. Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters. Nat. Microbiol. 8, 860–874, https://doi.org/10.1038/s41564-023-01352-8 (2023).
doi: 10.1038/s41564-023-01352-8
pubmed: 37012419
pmcid: 10159847
Stauft, C. B. et al. Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants. Nat. Commun. 14, 3393 (2023).
pubmed: 37296125
pmcid: 10250859
doi: 10.1038/s41467-023-39090-4
Afkhami, S. et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell 185, 896–915.e819 (2022).
pubmed: 35180381
pmcid: 8825346
doi: 10.1016/j.cell.2022.02.005
Minor, P. D. The molecular biology of poliovaccines. J. Gen. Virol. 73, 3065–3077 (1992).
pubmed: 1335021
doi: 10.1099/0022-1317-73-12-3065
Platt, L. R., Estivariz, C. F. & Sutter, R. W. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J. Infect. Dis. 210, S380–S389 (2014).
pubmed: 25316859
doi: 10.1093/infdis/jiu184
Almazan, F. et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBio 4, e00650–00613 (2013).
pubmed: 24023385
pmcid: 3774192
doi: 10.1128/mBio.00650-13
Gutierrez-Alvarez, J. et al. Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice. Proc. Natl Acad. Sci. USA 118, e2111075118, https://doi.org/10.1073/pnas.2111075118 (2021).
doi: 10.1073/pnas.2111075118
pubmed: 34686605
pmcid: 8639359
Zhang, X. et al. A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. Cell 184, 2229–2238.e2213 (2021).
pubmed: 33691138
pmcid: 7901297
doi: 10.1016/j.cell.2021.02.044
Netland, J. et al. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology 399, 120–128 (2010).
pubmed: 20110095
doi: 10.1016/j.virol.2010.01.004
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 Coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501.e1415 (2020).
pubmed: 32473127
pmcid: 7237901
doi: 10.1016/j.cell.2020.05.015
Peng, Y. et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336–1345 (2020).
pubmed: 32887977
pmcid: 7611020
doi: 10.1038/s41590-020-0782-6
Yoo, J. S. et al. SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis. Nat. Commun. 12, 6602 (2021).
pubmed: 34782627
pmcid: 8594428
doi: 10.1038/s41467-021-26910-8
Kimura, I. et al. Sarbecovirus ORF6 proteins hamper induction of interferon signaling. Cell Rep. 34, 108916 (2021).
pubmed: 33765414
pmcid: 7953434
doi: 10.1016/j.celrep.2021.108916
Zhang, Y. et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Iota. Proc. Natl Acad. Sci. USA 118, e2024202118, https://doi.org/10.1073/pnas.2024202118 (2021).
doi: 10.1073/pnas.2024202118
pubmed: 34021074
pmcid: 8201919
Wagner, C. et al. Positive selection underlies repeated knockout of ORF8 in SARS-CoV-2 evolution. Nat. Commun. 15, 3207 (2024).
pubmed: 38615031
pmcid: 11016114
doi: 10.1038/s41467-024-47599-5
Liu, Y. et al. A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Nat. Commun. 13, 4337 (2022).
pubmed: 35896528
pmcid: 9326133
doi: 10.1038/s41467-022-31930-z
Silvas, J. A. et al. Contribution of SARS-CoV-2 accessory proteins to viral pathogenicity in K18 human ACE2 transgenic mice. J. Virol. 95, e0040221 (2021).
pubmed: 34133899
doi: 10.1128/JVI.00402-21
Melade, J. et al. A simple reverse genetics method to generate recombinant coronaviruses. EMBO Rep. 23, e53820 (2022).
pubmed: 35239997
pmcid: 9066064
doi: 10.15252/embr.202153820
Kipfer, E. T. et al. Rapid cloning-free mutagenesis of new SARS-CoV-2 variants using a novel reverse genetics platform. eLife 12, RP89035 (2023).
pubmed: 37988285
pmcid: 10662946
doi: 10.7554/eLife.89035
Cattin-Ortola, J. et al. Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation. Nat. Commun. 12, 5333 (2021).
pubmed: 34504087
pmcid: 8429659
doi: 10.1038/s41467-021-25589-1
Chen, I. P. et al. Viral E protein neutralizes BET protein-mediated post-entry antagonism of SARS-CoV-2. Cell Rep. 40, 111088 (2022).
pubmed: 35839775
pmcid: 9234021
doi: 10.1016/j.celrep.2022.111088
Vann, K. R. et al. Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection. Structure 30, 1224–1232.e1225 (2022).
pubmed: 35716662
pmcid: 9212912
doi: 10.1016/j.str.2022.05.020
Hadfield, J. et al. Nextstrain: real-time tracking of pathogen evolution. https://nextstrain.org/ncov/gisaid/global/all-time?c=gt-ORF8_8&l=radial (2018).
Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834–838 (2020).
pubmed: 32408338
pmcid: 7394720
doi: 10.1038/s41586-020-2342-5
Ulrich, L. et al. Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta. Nature 602, 307–313 (2022).
pubmed: 34937050
doi: 10.1038/s41586-021-04342-0
Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance 25, 2000045, https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045 (2020).
doi: 10.2807/1560-7917.ES.2020.25.3.2000045
pubmed: 31992387
pmcid: 6988269
Yu, X., Fournier, S., Allison, J. P., Sharpe, A. H. & Hodes, R. J. The role of B7 costimulation in CD4/CD8 T cell homeostasis. J. Immunol. 164, 3543–3553 (2000).
pubmed: 10725709
doi: 10.4049/jimmunol.164.7.3543
Wong, S. C., Oh, E., Ng, C. H. & Lam, K. P. Impaired germinal center formation and recall T-cell-dependent immune responses in mice lacking the costimulatory ligand B7-H2. Blood 102, 1381–1388 (2003).
pubmed: 12714510
doi: 10.1182/blood-2002-08-2416
Roussel, L. & Vinh, D. C. ICOSL in host defense at epithelial barriers: lessons from ICOSLG deficiency. Curr. Opin. Immunol. 72, 21–26 (2021).
pubmed: 33756276
doi: 10.1016/j.coi.2021.03.001
Jung, J. et al. Transmission and infectious SARS-CoV-2 shedding kinetics in vaccinated and unvaccinated individuals. JAMA Netw. Open 5, e2213606 (2022).
pubmed: 35608859
pmcid: 9131744
doi: 10.1001/jamanetworkopen.2022.13606
Martinez-Baz, I. et al. Effect of COVID-19 vaccination on the SARS-CoV-2 transmission among social and household close contacts: a cohort study. J. Infect. Public Health 16, 410–417 (2023).
pubmed: 36724697
pmcid: 9876028
doi: 10.1016/j.jiph.2023.01.017
Miteva, D. et al. Mucosal COVID-19 vaccines: risks, benefits and control of the pandemic. World J. Virol. 11, 221–236 (2022).
pubmed: 36188733
pmcid: 9523321
doi: 10.5501/wjv.v11.i5.221
Singanayagam, A. et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect. Dis. 22, 183–195 (2022).
pubmed: 34756186
pmcid: 8554486
doi: 10.1016/S1473-3099(21)00648-4
Mongin, D. et al. Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection. Nat. Commun. 14, 5452 (2023).
pubmed: 37673865
pmcid: 10482859
doi: 10.1038/s41467-023-41109-9
Thi Nhu Thao, T. et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature 582, 561–565 (2020).
doi: 10.1038/s41586-020-2294-9
Chu, D. K. W. et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin. Chem. 66, 549–555 (2020).
pubmed: 32031583
pmcid: 7108203
doi: 10.1093/clinchem/hvaa029
Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).
pubmed: 29203879
pmcid: 5715110
doi: 10.1038/s41598-017-17204-5
Protocol: Real-time RT-PCR assays for the detection of SARS-CoV-2 Institut Pasteur, Paris.
Wernike, K. et al. Multi-species ELISA for the detection of antibodies against SARS-CoV-2 in animals. Transbound. Emerg. Dis. 68, 1779–1785 (2021).
pubmed: 33191578
doi: 10.1111/tbed.13926
Stegmann, K. M. et al. Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication. iScience 25, 104293 (2022).
pubmed: 35492218
pmcid: 9035612
doi: 10.1016/j.isci.2022.104293
Breithaupt, A., Sick, F., Golender, N., Beer, M. & Wernike, K. Characterization of experimental Shuni virus infection in the mouse. Vet. Pathol. 60, 341–351 (2023).
pubmed: 36803054
doi: 10.1177/03009858231155402
Bussmann, B. M., Reiche, S., Jacob, L. H., Braun, J. M. & Jassoy, C. Antigenic and cellular localisation analysis of the severe acute respiratory syndrome coronavirus nucleocapsid protein using monoclonal antibodies. Virus Res. 122, 119–126 (2006).
pubmed: 16920216
doi: 10.1016/j.virusres.2006.07.005
Rihn, S. J. et al. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. PLoS Biol. 19, e3001091 (2021).
pubmed: 33630831
pmcid: 7906417
doi: 10.1371/journal.pbio.3001091
Miyamoto, Y. et al. SARS-CoV-2 ORF6 disrupts nucleocytoplasmic trafficking to advance viral replication. Commun. Biol. 5, 483 (2022).
pubmed: 35590097
pmcid: 9120032
doi: 10.1038/s42003-022-03427-4